Changes in Beneficial Ownership · 4
Olema Pharmaceuticals, Inc.
OLMANASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
form4-06232026_090620.xml
Filing details
- Report period
- 2026-06-18
- Issuer
- Olema Pharmaceuticals, Inc.
- Issuer CIK
- 0001750284
- Trading symbol
- OLMA
Reporting owner 1
- Name
- Garland J. Scott
- Reporting owner CIK
- 0001533228
- Relationship
- Director
- Address
- C/O OLEMA PHARMACEUTICALS, INC., 780 BRANNAN ST, SAN FRANCISCO, CA, 94103
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy) | 9.51 | 2026-06-18 | A · Form 4 | 29,500 | A | 0 | [F1] | 2036-06-18 | Common Stock | 29,500 | 29,500 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.↩ 1
Signature 1
- Signed
- /s/ Shawnte Mitchell, Attorney-in-Fact
- Date
- 2026-06-23
Company context
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.
Current securities
Recent company filings
- SCHEDULE 13D/A - filed by BIOTECHNOLOGY VALUE FUND L P regarding Olema Pharmaceuticals, Inc.Oct 16, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsOct 15, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureAug 13, 2026
- 10-Q filingAug 10, 2026
- Results of Operations and Financial ConditionAug 10, 2026